This latest equity financing includes support from new US and international institutional investors, including a wholly-owned subsidiary of the Abu Dhabi Investment Authority, BB Biotech AG, Julius Baer, Singapore-based EDBI, and Sequoia Capital China.
Existing investors that also participated include Fidelity Management and Research company, Pictet, Viking Global Investors, ArrowMark Partners, and Alexandria Venture Investments.
The funding will help drive the company's continued execution of its rapidly growing pipeline of 19 development candidates including 10 programmes in clinical trials.
Proceeds will also be used to further Moderna's investment in its research engine and other 2018/2019 priorities.
Privately held Moderna is developing mRNA vaccines and therapeutics as a new class of medicines for infectious diseases, cancer (immuno-oncology), rare liver diseases, cardiovascular and pulmonary diseases, through proprietary development and collaborations with strategic partners.
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies
CirCode Biomed's IND application for HM2002 receives FDA clearance
CeleCor Therapeutics completes Phase 3 trial of new anti-platelet agent for heart attack
Sarepta receives UK approval to continue dosing in ELEVIDYS ENVISION study
Ionis reports positive Phase 3 results for olezarsen in moderate hypertriglyceridemia
Nordic Bioscience launches new Endotrophin assay
AbbVie and ADARx Pharmaceuticals partner on next-generation siRNA therapies
Otsuka's leukaemia drug ponatinib launched on Fangzhou platform
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Avacta Therapeutics reports positive Phase 1 data for lead candidate
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
Primo Biotechnology's Taoyuan facility granted PIC/S GMP Certification
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment